March 7, 2024 News by Margarida Maia, PhD ACTRIMS 2024: An antihistamine may speed MS disease progression The antihistamine clemastine accelerated disease progression by more than five times in some adults with progressive multiple sclerosis (MS) who received it in a Phase 1/2 trial, new data show. Joanna Kocot, PhD, a neuroscientist at the National Institutes of Health (NIH), showed that this effect is at least…
March 6, 2024 News by Marisa Wexler, MS ACTRIMS 2024: 2 treatments to aid remyelination near clinical trials Convelo Therapeutics is developing two experimental oral treatments to promote myelin repair in multiple sclerosis (MS) and both have shown promise in preclinical models. The company is in the final stages of safety studies in large animals. Once those studies are done, it plans to start studies that…
March 6, 2024 News by Margarida Maia, PhD ACTRIMS 2024: Tolebrutinib fails to eliminate iron rim lesions in Phase 2 trial Nearly one year of treatment with tolebrutinib, an oral small molecule being developed by Sanofi, failed to eliminate iron rim lesions in adults with multiple sclerosis (MS), according to data from a small Phase 2 clinical trial. Researchers are continuing to examine study results to determine…
March 5, 2024 News by Marisa Wexler, MS ACTRIMS 2024: Evobrutinib fails to show superiority to Aubagio in Phase 3 trials The experimental BTK inhibitor evobrutinib was no better than Aubagio (teriflunomide) at preventing relapses, reducing brain lesions, or slowing disability progression in people with relapsing forms of multiple sclerosis (MS), according to data from two Phase 3 trials. Both medications had generally similar safety profiles, although increases…
March 5, 2024 News by Marisa Wexler, MS ACTRIMS 2024: Progressive MS patients show gains in NG-01 OLE Repeated treatment with the mesenchymal stem cell therapy NG-01 led to gains in mobility and cognition, along with patient-reported quality of life, for most people with progressive multiple sclerosis (MS) in an extension study. Markers of nerve damage were also reduced, indicating significant nerve-protecting effects. Dimitrios Karussis, MD,…
March 4, 2024 News by Marisa Wexler, MS ACTRIMS 2024: Vidofludimus calcium lowers NfL levels in progressive MS Treatment with Immunic Therapeutics‘ experimental oral therapy vidofludimus calcium (IMU-838) lowered the levels of a nerve damage marker in people with all subtypes of progressive multiple sclerosis (MS), including those without recent inflammatory activity. That’s according to an interim analysis of data from a Phase 2 study,…
March 4, 2024 News by Marisa Wexler, MS ACTRIMS 2024: Most patients relapse-free after 6 years on Zeposia About two-thirds of people with relapsing forms of multiple sclerosis (MS) remained completely free from relapses over six years of treatment with Zeposia (ozanimod) in the DAYBREAK clinical trial. Most also saw no sustained disability progression during that period and the mean number of new or enlarging lesions…
March 1, 2024 News by Mary Chapman Stories and connections emphasized for this year’s MS Awareness Month Multiple sclerosis (MS), a neurodegenerative disease thought to affect more than 1.8 million people globally, can impact many aspects of daily life. So for Multiple Sclerosis Awareness Month, observed each March, this year’s focus is on the MS experience and the importance of social connections. Multiple Sclerosis…
March 1, 2024 News by Marisa Wexler, MS ACTRIMS 2024: Molecule made by gut bacteria seen to ease MS in mice Supplements of indole 3-lactate (ILA), a molecule made by gut bacteria, significantly reduced disease severity and promoted myelin repair in mouse models of multiple sclerosis (MS). That’s according to new findings presented by Larissa Jank, PhD, a postdoctoral researcher at Johns Hopkins University, at the Americas Committee for Treatment…
February 29, 2024 News by Andrea Lobo, PhD Briumvi for relapsing MS now available for patients in Europe Briumvi (ublituximab-xiiy), an approved treatment for relapsing forms of multiple sclerosis (MS), is now available to patients in Europe, where itās being marketed by Neuraxpharm. The infusion therapy, developed by TG Therapeutics, was first launched in Germany, with additional rollouts following in other European countries. Under…
February 29, 2024 News by Margarida Maia, PhD Australian researchers win grants to study immune system’s role in MS Two researchers from The University of Western Australia (UWA) have received grants from MS Australia for work that may help scientists better understand how an immune system gone awry can cause multiple sclerosis (MS). Belinda Kaskow, PhD, a teaching and research fellow at UWAās School of Biomedical Sciences,…
February 28, 2024 News by Margarida Maia, PhD Balance training helps both in easing fatigue, restoring balance: Small trial Both balance and endurance training can help to ease fatigue in people with multiple sclerosis (MS) ā but if problems with balance are a concern, then balance training would be the best choice as it targets both fatigue and balance, a small study found. The study, āFatigue may…
February 28, 2024 News by Marisa Wexler, MS Association between proteins may predict early MS disease activity An association between the proteins IgG1 and CXCL10 in the fluid around the brain may help predict the risk of future disease activity for people in the early stages of multiple sclerosis (MS). That’s according to “CXCL10/IgG1 Axis in Multiple Sclerosis as a Potential Predictive Biomarker…
February 27, 2024 News by Margarida Maia, PhD Stem cell therapy for MS seen to lower mitochondrial DNA in study People with multiple sclerosis (MS) have higher amounts of mitochondrial DNA in their spinal fluid, which surrounds the brain and spinal cord, than do their healthy counterparts, a small study found. Mitochondria are small cellular organelles that produce most of the energy needed to power cells. These cell powerhouses…
February 27, 2024 News by Margarida Maia, PhD Black MS patients in US score poorly on walking, physical ability tests Black people with multiple sclerosis (MS) scored lower on tests of walking and physical function than did white patients, regardless of social determinants of health such as education or income, a U.S. study reported. These findings add to a growing understanding of how MS manifests in Black people, and…
February 26, 2024 News by Marisa Wexler, MS Dark rim on MS lesions seen with standard MRI may mark activity An imaging feature called the T1-dark rim, which is visible on standard MRI scans of people with multiple sclerosis (MS), could help to identify paramagnetic rim lesions (PRLs), a study suggests. PRLs are regions of chronic active inflammation that cause ongoing nerve damage. They’re associated with disease activity and…
February 26, 2024 News by Andrea Lobo, PhD High incidence, prevalence of pediatric-onset MS in Sweden Sweden has a consistently high incidence and prevalence of pediatric-onset multiple sclerosis (PoMS), according to a recently published study. Incidence measures the number of new cases identified during a certain period, while prevalence measures the proportion of people in the population with the condition. Data show the disease is…
February 23, 2024 News by Margarida Maia, PhD Most MS patients stay relapse-free 6 years after stem cell transplant About 4 in 5 people with relapsing-remitting multiple sclerosis (RRMS) who receive a stem cell transplant remain free of relapses for at least six years, and this may translate into being able to get back to work, a small study from Norway suggests. The study, āAutologous hematopoietic…
February 23, 2024 News by Steve Bryson, PhD Magnetic brain stimulation aids motor function, balance in MS trial Coupling a noninvasive brain stimulation procedure with an intensive rehabilitation program significantly improved motor function and balance in adults with relapsing-remitting multiple sclerosis (RRMS), a randomized clinical trial finds. High-frequency repetitive transcranial magnetic stimulation (rTMS) is a noninvasive treatment approach that delivers pulses of magnetic fields to modulate nerve…
February 22, 2024 News by Margarida Maia, PhD Complement protein activation is linked to more severe MS Complement proteins, especially when activated in the brain and spinal cord, may contribute to nerve cell damage and more severe multiple sclerosis (MS) symptoms, a study that offers insights into a possible therapeutic target suggests. The study, āComplement Activation Is Associated With Disease Severity in Multiple Sclerosis,ā was…
February 22, 2024 News by Marisa Wexler, MS Prioritize high-efficacy DMTs for children with MS, study suggests Children with multiple sclerosis (MS) who start on high-efficacy therapies experience fewer relapses and reduced MRI disease activity in the following years, compared with those who are treated first with moderate-efficacy therapies, according to a new study. Rates of severe side effects are similar for both groups, but the…
February 21, 2024 News by Margarida Maia, PhD Melatonin at night may help with morning balance, strength in MS Taking melatonin before bedtime may help balance and muscle strength in people living with multiple sclerosis (MS), according to a study from Tunisia. Those benefits are in addition toĀ making for more restful sleep. While the findings come from a small number of patients, they suggest melatonin supplements may…
February 21, 2024 News by Andrea Lobo, PhD Use of DMTs in pregnancy on big upswing recently: Study in France More women with multiple sclerosis (MS) got pregnant in recent years, probably linked to a significantly higher use of disease-modifying therapies (DMTs) during pregnancy, according to a nationwide study in France. DMTs are a type of treatment that can alter MS course, by reducing the risk of relapses,…
February 21, 2024 News by Marisa Wexler, MS Treatment of progressive MS hits milestones in recent years: Review Treatment options for progressive types of multiple sclerosis (MS) have expanded dramatically over the past decade, and several promising experimental therapies are in late stages of clinical development, a new review paper highlights. The study, “Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and…
February 20, 2024 News by Lindsey Shapiro, PhD Chronic inflammatory lesions linked to more aggressive MS in US study The presence in the brain of chronic inflammatory lesions ā called paramagnetic rim lesions (PRLs) ā in people with multiple sclerosis (MS) is associated with a greater relapse burden and faster disability progression in the long term, according to a new U.S. study. Among more than 150 patients who…
February 20, 2024 News by Margarida Maia, PhD Nabiximols, cannabis-based spray, eases spasticity in real-world use Nabiximols, a cannabis-based oral spray sold as Sativex, was reported to considerably ease spasticity ā unusual muscle tightness or stiffness ā in about two-thirds of the multiple sclerosis (MS) patients using it for three months in a real-world study in Germany. For most patients, the treatment also…
February 19, 2024 News by Lindsey Shapiro, PhD Sanofi launches Phase 3 frexalimab trials after positive Phase 2 data Bolstered by Phase 2 trial data showing that frexalimab safely reduces the number of brain lesions in people with relapsing forms of multiple sclerosis (MS), developer Sanofi has launched a pair of Phase 3 studies that will test the investigational therapy in relapsing and progressive MS. One of…
February 19, 2024 News by Margarida Maia, PhD Caffeine tablets may help MS patients’ balance, mobility Taking caffeine tablets ā the equivalent to about two cups of coffee a day ā may help people with multiple sclerosis (MS) keep their balance and move more easily, which could aid their quality of life, a small study suggests. While the tablets may…
February 16, 2024 News by Marisa Wexler, MS Online therapy platform found to boost mental health of patients COMPASS, a digital tool that provides support for managing the daily challenges of living with a long-term health condition such as multiple sclerosis (MS), significantly reduces psychological distress and improves mental health in these patients, data from a randomized clinical trial show. The intervention consists of multiple online modules…
February 16, 2024 News by Lindsey Shapiro, PhD Larger trials needed to evaluate intermittent fasting for MS: Review An intermittent fasting (IF) diet may lead to immune and metabolic alterations that ease multiple sclerosis (MS) symptoms and improve quality of life, a recent review of published studies suggests. While evidence from these few small clinical trials indicates an IF diet…